4 results
see protocol summary
The primary objective is to determine if the addition of daratumumab to VRd will prolong PFS defined as the time from the date of randomization to the date of disease progression (assessed by International Myeloma Working Group [IMWG] criteria) or…
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.
To test whether tACS in a theta frequency enhances extinction of physiological stress responses to exposure to anxiety- or trauma-related stimuli or memories. Secondarily, to examine the influence of baseline neuroendocrinological response, baseline…